Nicole B Carnegie1, Steven M Goodreau, Albert Liu, Eric Vittinghoff, Jorge Sanchez, Javier R Lama, Susan Buchbinder. 1. *Joseph J. Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI; †Department of Anthropology, University of Washington, Seattle, WA; ‡San Francisco Department of Public Health, San Francisco, CA; §Department of Epidemiology & Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA; and ‖Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
Abstract
BACKGROUND: We aim to identify optimal strategies for deploying pre-exposure prophylaxis among men who have sex with men (MSM) in the United States and Peru to maximize population-level effectiveness in an efficient manner. We use epidemic models to simulate the impact of targeting strategies. Most studies have focused on targeting either the general population or high-risk MSM. Alternative strategies, including serodiscordant couples, may better balance effectiveness and efficiency. METHODS: We use dynamic stochastic sexual network models based on exponential-family random graph modeling, parameterized from behavioral surveys of MSM in the United States and Peru. These models represent main partnerships and casual contacts separately, permitting modeling of interventions targeting men whose risk derives from combinations of relational types. We also model varying rates of uptake and adherence to pre-exposure prophylaxis (PrEP). We assess sensitivity of results to risk compensation through increases in condomless casual contacts and condomless sex in main partnerships. RESULTS: Targeting all men who are not exclusively insertive has the largest impact on HIV incidence, but targeting only those with high levels of casual activity yields comparable results using fewer person-years on PrEP. The effect is robust to risk compensation in the United States, but less so in Peru. Targeting serodiscordant main partnerships does not significantly impact incidence, but requires fewer person-years on PrEP per infection averted than other strategies. CONCLUSIONS: PrEP could be effective in reducing new infections at the population level in both settings. Serodiscordant partnerships are an attractive component of a targeting program, but targeting should include other high-risk men.
BACKGROUND: We aim to identify optimal strategies for deploying pre-exposure prophylaxis among men who have sex with men (MSM) in the United States and Peru to maximize population-level effectiveness in an efficient manner. We use epidemic models to simulate the impact of targeting strategies. Most studies have focused on targeting either the general population or high-risk MSM. Alternative strategies, including serodiscordant couples, may better balance effectiveness and efficiency. METHODS: We use dynamic stochastic sexual network models based on exponential-family random graph modeling, parameterized from behavioral surveys of MSM in the United States and Peru. These models represent main partnerships and casual contacts separately, permitting modeling of interventions targeting men whose risk derives from combinations of relational types. We also model varying rates of uptake and adherence to pre-exposure prophylaxis (PrEP). We assess sensitivity of results to risk compensation through increases in condomless casual contacts and condomless sex in main partnerships. RESULTS: Targeting all men who are not exclusively insertive has the largest impact on HIV incidence, but targeting only those with high levels of casual activity yields comparable results using fewer person-years on PrEP. The effect is robust to risk compensation in the United States, but less so in Peru. Targeting serodiscordant main partnerships does not significantly impact incidence, but requires fewer person-years on PrEP per infection averted than other strategies. CONCLUSIONS: PrEP could be effective in reducing new infections at the population level in both settings. Serodiscordant partnerships are an attractive component of a targeting program, but targeting should include other high-risk men.
Authors: Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Peter L Anderson; David V Glidden; Albert Liu; Susan Buchbinder; Javier R Lama; Juan Vicente Guanira; Vanessa McMahan; Lane R Bushman; Martín Casapía; Orlando Montoya-Herrera; Valdilea G Veloso; Kenneth H Mayer; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Esper Georges Kallás; Robert M Grant Journal: Sci Transl Med Date: 2012-09-12 Impact factor: 17.956
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Gabriela B Gomez; Annick Borquez; Carlos F Caceres; Eddy R Segura; Robert M Grant; Geoff P Garnett; Timothy B Hallett Journal: PLoS Med Date: 2012-10-09 Impact factor: 11.069
Authors: Timothy B Hallett; Jared M Baeten; Renee Heffron; Ruanne Barnabas; Guy de Bruyn; Íde Cremin; Sinead Delany; Geoffrey P Garnett; Glenda Gray; Leigh Johnson; James McIntyre; Helen Rees; Connie Celum Journal: PLoS Med Date: 2011-11-15 Impact factor: 11.069
Authors: Steven M Goodreau; Nicole B Carnegie; Eric Vittinghoff; Javier R Lama; Jorge Sanchez; Beatriz Grinsztejn; Beryl A Koblin; Kenneth H Mayer; Susan P Buchbinder Journal: PLoS One Date: 2012-11-29 Impact factor: 3.240
Authors: Andrew N Phillips; Valentina Cambiano; Fumiyo Nakagawa; Alison E Brown; Fiona Lampe; Alison Rodger; Alec Miners; Jonathan Elford; Graham Hart; Anne M Johnson; Jens Lundgren; Valerie C Delpech Journal: PLoS One Date: 2013-02-15 Impact factor: 3.240
Authors: Samuel M Jenness; Kevin M Weiss; Steven M Goodreau; Thomas Gift; Harrell Chesson; Karen W Hoover; Dawn K Smith; Albert Y Liu; Patrick S Sullivan; Eli S Rosenberg Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Samuel M Jenness; Steven M Goodreau; Eli Rosenberg; Emily N Beylerian; Karen W Hoover; Dawn K Smith; Patrick Sullivan Journal: J Infect Dis Date: 2016-07-14 Impact factor: 5.226
Authors: Shana D Hughes; Nicolas Sheon; Erin V W Andrew; Stephanie E Cohen; Susanne Doblecki-Lewis; Albert Y Liu Journal: Med Anthropol Date: 2018-01-19
Authors: Ian W Holloway; Diane Tan; Robert A Bednarczyk; Vincent L Fenimore; Laura Randall; Chelsea S Lutz; Paula M Frew Journal: Arch Sex Behav Date: 2019-10-18
Authors: Elizabeth C Pasipanodya; Michael J Li; Sonia Jain; Xiaoying Sun; Jessica Tobin; Eric Ellorin; Michael Dube; Eric S Daar; Katya Corado; Joel Milam; Jill Blumenthal; Sheldon H Morris; David J Moore Journal: AIDS Behav Date: 2020-11
Authors: Samuel M Jenness; Akshay Sharma; Steven M Goodreau; Eli S Rosenberg; Kevin M Weiss; Karen W Hoover; Dawn K Smith; Patrick Sullivan Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Brian Mustanski; Ethan Morgan; Richard DʼAquila; Michelle Birkett; Patrick Janulis; Michael E Newcomb Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Paula M Luz; Benjamin Osher; Beatriz Grinsztejn; Rachel L Maclean; Elena Losina; Madeline E Stern; Claudio J Struchiner; Robert A Parker; Kenneth A Freedberg; Fabio Mesquita; Rochelle P Walensky; Valdilea G Veloso; A David Paltiel Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396